The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
天真笑白完成签到,获得积分10
1秒前
1秒前
111完成签到,获得积分10
1秒前
3秒前
3秒前
怡然的醉易完成签到 ,获得积分10
4秒前
烂漫的谷波完成签到,获得积分10
5秒前
5秒前
Pluto发布了新的文献求助20
5秒前
打打应助葳蕤采纳,获得10
5秒前
浅惜完成签到,获得积分10
5秒前
11_aa发布了新的文献求助10
5秒前
闪闪烧鹅发布了新的文献求助10
5秒前
大个应助zzy采纳,获得10
5秒前
噜啦啦发布了新的文献求助10
7秒前
8秒前
David完成签到,获得积分10
8秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
我是老大应助科研通管家采纳,获得10
9秒前
彭于晏应助科研通管家采纳,获得10
9秒前
大个应助科研通管家采纳,获得10
9秒前
CipherSage应助科研通管家采纳,获得10
9秒前
Jasper应助科研通管家采纳,获得10
9秒前
隐形曼青应助科研通管家采纳,获得10
9秒前
研友_VZG7GZ应助科研通管家采纳,获得10
9秒前
传奇3应助科研通管家采纳,获得10
9秒前
9秒前
科研通AI2S应助科研通管家采纳,获得10
9秒前
弗一昂发布了新的文献求助10
10秒前
Windycityguy完成签到,获得积分10
10秒前
铍铍侠发布了新的文献求助10
11秒前
40873完成签到,获得积分10
11秒前
LLL发布了新的文献求助10
11秒前
12秒前
12秒前
13秒前
小蘑菇应助qindong采纳,获得10
14秒前
奋斗的绝悟应助tzt采纳,获得10
14秒前
高分求助中
Evolution 3rd edition 1500
保险藏宝图 1000
Lire en communiste 1000
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 700
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 700
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3183165
求助须知:如何正确求助?哪些是违规求助? 2833280
关于积分的说明 7993323
捐赠科研通 2495441
什么是DOI,文献DOI怎么找? 1331495
科研通“疑难数据库(出版商)”最低求助积分说明 636303
邀请新用户注册赠送积分活动 603474